El declive de la linfadenectomía axilar en el cáncer de mama. Evolución de su indicación durante los últimos 20 años

Novoa, Alejandra García; Nebril, Benigno Acea; Casal-Beloy, Isabel; Bouzón-Alejandro, Alberto; Garea, Carmen Cereijo; Gómez-Dovigo, Alba; Builes-Ramírez, Sergio; Santiago, Paz; Mosquera-Oses, Joaquín

doi:10.1016/j.ciresp.2019.01.010

Cited by 8 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When it comes to the axillary approach, a Spanish research that evaluated this approach in breast cancer for 20 years concluded that the percentage of axillary lymphadenectomy went from 91% at the beginning of the study to 34% at the end, which was attributed to the introduction of the sentinel lymph node biopsy and international criteria that modified the indication of axillary lymphadenectomy, avoiding morbidities associated with this procedure, especially lymphedema. 20 However, the results of the present study showed that 67.2% of women underwent axillary lymphadenectomy, in contrast to worldwide occurrences.…”

Section: Discussioncontrasting

confidence: 75%

Sociodemographic and Clinical-pathological Study of Molecular Subtitles of Breast Carcinoma in a Reference Unit of Maranhão

Reis

Teixeira

Medeiros

et al. 2020

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Objective To evaluate the distribution of the main sociodemographic and clinical-pathological characteristics in women with breast cancer according to the molecular profile by immunohistochemistry. Methods A cross-sectional, retrospective, analytical and quantitative study was performed, with an analysis of 137 medical records from January 2015 to December 2018 of women attending the High Complexity in Oncology Unit of the city of Imperatriz, state of Maranhão, Brazil. The immunohistochemical profile of tumors based on the estrogen and progesterone receptor, Human Epidermal growth factor Receptor-type 2 (HER2) overexpression and Ki67 cell proliferation index was defined, from which six molecular subtypes were determined: luminal A, luminal B-HER2 negative, luminal B-HER2 positive, triple negative, overexpression of HER2 and inconclusive. Results A total of 52.6% of the patients were postmenopausal, mean age 52.1 years old, brown (56.2%), had a schooling level < 9 years (40%), staging > IIB (52.6%) and 23.4% had metastasis. Invasive ductal carcinoma accounted for 84.7%, tumor size was 2 to 5 cm (48.9%), with lymph node involvement (56.2%), axillary lymphadenectomy in 67.2%, and mastectomy in 73.7% of the patients. The most frequent molecular subtype was the luminal B-HER2 negative (36.5%), and the luminal A subtype showed characteristics of better prognosis when compared with the others. Conclusion It was concluded that in the association of molecular subtypes with sociodemographic and clinical-pathological characteristics, there were no statistically significant results obtained, except for complementary therapy, referring to hormone therapy, and there was a high index of metastasis at diagnosis, which was a worrying factor and indicative of failures in the screening and early diagnosis of this population.

show abstract

Section: Discussioncontrasting

confidence: 75%